334 completed, 61 unknown, 32 recruiting, 28 terminated. 178 Phase 3, 125 Phase 4, 91 Phase 2, 36 Phase 1, 24 Not applicable.
Follow Adalimumab: new trials by email Literature Review of Adalimumab trials Research Report on Adalimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Apremilast and Adalimumab in Psoriatic Arthritis Patients Adalimumab, Apremilast - Psoriatic Arthritis, Ultrasound Assessment | Not applicable | Not yet recruiting | Tanta University | 60 | 2026-12-30 | 2026-09-08 |
| Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis Blood sample, Adalimumab Injection - Uveitis, Chronic Disease | Phase 4 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 320 | 2026-12-01 | 2026-07-10 |
| Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab bimekizumab, adalimumab - Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis | Phase 3 | Not yet recruiting | University Hospital, Rouen | 150 | 2026-10-15 | 2026-09-23 |
| Subconjunctival Humira for Boston Keratoprosthesis Adalimumab Injection - Penetrating Keratoplasty, Multiple Graft Failure | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 8 | 2026-10-01 | 2026-08-31 |
| A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon Adalimumab, Guselkumab, SDL-001 - Healthy Subjects | Phase 1 | Not yet recruiting | Surmount Services, Inc. | 18 | 2026-09-15 | 2026-08-26 |
| Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis Etanercept, Adalimumab, Upadacitinib - Arthritis, Rheumatoid | Not yet recruiting | Tufts Medical Center | 18 | 2026-09-01 | 2026-07-22 | |
| Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial Adalimumab/Biosimilar - Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior | Phase 4 | Not yet recruiting | Nisha Acharya | 160 | 2026-09-01 | 2026-07-13 |
| An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) Adalimumab, Placebo - REM Sleep Behavior Disorder | Phase 2 | Recruiting | Yale University | 108 | 2026-08-17 | 2026-10-08 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD GenSci120 150 mg, GenSci120 600 mg, GenSci120 1000 mg - Rheumatoid Arthritis | Phase 2 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 450 | 2026-04-30 | 2026-05-22 |
| Biologics in Folliculitis Decalvans : an Adaptative Trial Research Adalimumab, Ustekinumab, Baricitinib - Folliculitis Decalvans (FD) | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 120 | 2026-04-01 | 2025-12-05 |
| Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Non-Interventional Study - Ulcerative Colitis | Active not recruiting | Pfizer | 4000 | 2026-04-01 | 2026-10-15 | |
| A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab - Type 1 Diabetes, New Onset | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 120 | 2026-03-10 | 2026-10-16 |
| Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab - Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) | Not yet recruiting | Assiut University | 95 | 2026-03-01 | 2026-03-27 | |
| TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response Upadacitinib, Infliximab Dose Intensification, Adalimumab Dose Intensification - Crohn Disease (CD) | Phase 4 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 312 | 2026-03-01 | 2026-06-09 |
| Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease Infliximab, Adalimumab, Vedolizumab - Inflamatory Bowel Disease, Crohn Disease (CD) | Recruiting | Shanghai 10th People's Hospital | 198 | 2026-01-16 | 2026-07-10 | |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis Methotrexate (MTX), Azathioprine (AZA), Adalimumab - Relapsing Polychondritis | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2025-11-11 | 2026-09-02 |
| A Study of LAD191 in Adults With Hidradenitis Suppurativa LAD191, Placebo, Adalimumab - Hidradenitis Suppurativa | Phase 2 | Recruiting | Almirall, S.A. | 200 | 2025-11-05 | 2026-05-11 |
| Evaluation of IL 12B Genetic Polymorphism (rs3213094) Humira - Psoriasis | Not applicable | Recruiting | South Valley University | 40 | 2025-08-01 | 2025-08-19 |
Showing 20 of 508. Sign in to see all of them.
Arthritis, Rheumatoid (159) · Crohn Disease (74) · Psoriasis (61) · Colitis, Ulcerative (41) · Arthritis, Psoriatic (39) · Spondylitis, Ankylosing (37) · Inflammatory Bowel Diseases (23) · Arthritis (22) · Uveitis (19) · Hidradenitis Suppurativa (16) · Spondylarthritis (16) · Arthritis, Juvenile (10) · Axial Spondyloarthritis (6) · Joint Diseases (6) · Skin Diseases (6)
Abbott (69) · AbbVie (37) · AbbVie (prior sponsor, Abbott) (30) · Pfizer (10) · Assistance Publique - Hôpitaux de Paris (9) · Eli Lilly and Company (9) · Alvotech Swiss AG (6) · Hoffmann-La Roche (6) · Janssen Research & Development, LLC (6) · Amgen (5) · Innovaderm Research Inc. (5) · Biocad (4) · Boehringer Ingelheim (4) · Glostrup University Hospital, Copenhagen (4) · Takeda (4)
United States (170) · Canada (90) · Germany (90) · Spain (80) · Poland (76) · United Kingdom (76) · France (69) · Czechia (65) · Belgium (53) · Russia (52) · Australia (48) · Netherlands (48) · Hungary (47) · Italy (47) · Bulgaria (39)
Beverly Paperiello (10) · Laura Redden, MD, PhD (5) · Martin Okun, MD (4)
PMID 27338778, PMID 29380251, PMID 30054164, PMID 33263165, PMID 36931693, PMID 32816215, PMID 34870800, PMID 36526796, PMID 36600185, PMID 36601090, PMID 39192350, PMID 26547918, PMID 29018564, PMID 31707982, PMID 33127856, PMID 34921355, PMID 36814062, PMID 37906417, PMID 38958913, PMID 19201775, PMID 19703304, PMID 20553600, PMID 21600054, PMID 21752491, PMID 22325170, PMID 22344964, PMID 22704916, PMID 24067881, PMID 24460746, PMID 25047021, PMID 25073879, PMID 26275429, PMID 27518661, PMID 27747583, PMID 28143815, PMID 28426849, PMID 28955494, PMID 29776990, PMID 29799960, PMID 29939254, PMID 30076156, PMID 30417277, PMID 31831079, PMID 32445184, PMID 34105767, PMID 34402466, PMID 34546360, PMID 34798036, PMID 35224732, PMID 35393269
2016 (13), 2009 (12), 2014 (11), 2015 (11), 2023 (6), 2017 (4), 2018 (4), 2019 (4), 2008 (3), 2005 (2), 2025 (2), R01AG095016 (1), R01DK135516 (1), R33DK070341 (1), U01DK134356 (1)